Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemiaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how visceral adipose tissue (VAT) area relates to the gut bacterial microbiome and circulating markers of metabolic endotoxemia in aging women. Metabolic endotoxemia is chronic low-grade inflammation driven by elevated circulating lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls. Researchers measured VAT by dual x-ray absorptiometry, assessed diet quality with a food frequency questionnaire, quantified plasma LPS, LPS-binding protein, and anti-LPS, anti-flagellin, and anti-lipoteichoic acid antibodies by ELISA, and performed metagenomic sequencing on fecal DNA. A parallel mouse experiment modeled metabolic endotoxemia by feeding female C57BL/6 mice diet-derived fecal LPS on high-fat or low-fat diets.
Who was studied?
The human cohort consisted of fifty postmenopausal women with a mean age of 78.8 years who already had existing DXA-based adipose measurements. Participants were selected from the extremes of visceral adiposity: twenty-five women with low VAT area (about 45.6 cm2) and twenty-five with high VAT area (about 177.5 cm2). This extreme-groups design allowed comparison of gut microbiome and endotoxemia markers across a wide range of visceral fat. The companion animal experiment used female C57BL/6 mice on high-fat or low-fat diets to model the human findings.
What were the most important findings?
The abstract indicates that high visceral adiposity in these postmenopausal women was linked to a gut bacterial microbiome shifted toward a pro-inflammatory profile compared to women with low VAT area. This shift accompanied signs of immunogenic metabolic endotoxemia, reflected in circulating LPS, LPS-binding protein, and antibody markers measured by ELISA. The provided abstract text is truncated before reporting the specific taxa, antibody levels, or mouse-model outcomes, so those detailed results cannot be stated here.
What are the greatest implications of this study?
The findings support a model in which visceral fat accumulation after menopause is accompanied by microbiome-driven inflammatory signaling, not just local adipose tissue changes. Pairing human cohort data with a mouse model of diet-derived LPS exposure suggests the gut microbiome and endotoxemia pathway may be a mechanistic link between visceral obesity and chronic disease risk in older women. This points to the gut barrier and circulating bacterial products as potential targets for reducing inflammation associated with abdominal obesity in aging populations.